(NASDAQ: CADL) Candel Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.65%.
Candel Therapeutics's earnings in 2025 is -$22,759,000.On average, 9 Wall Street analysts forecast CADL's earnings for 2025 to be -$23,320,799, with the lowest CADL earnings forecast at -$23,134,145, and the highest CADL earnings forecast at -$23,633,719. On average, 8 Wall Street analysts forecast CADL's earnings for 2026 to be -$55,568,062, with the lowest CADL earnings forecast at -$78,762,595, and the highest CADL earnings forecast at -$28,821,609.
In 2027, CADL is forecast to generate -$26,219,430 in earnings, with the lowest earnings forecast at -$60,794,381 and the highest earnings forecast at $40,926,685.